Drug Trial Radar · NCT03905603
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Last checked: Nov 20, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
144
Planned (sponsor's estimate)
Start
Oct 8, 2019
Primary completion
Apr 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- University of VirginiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 20 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the study is to determine the relative contributions of four established predictors of hyperandrogenism (luteinizing hormone \[LH\] secretion, ovarian response to recombinant human chorionic gonadotropin \[r-hCG\] administration, adrenal response to adrenocorticotropic hormone \[ACTH\] administration, and hyperinsulinemia) in older vs. young women with Polycystic Ovary Syndrome (PCOS) in a cross-sectional, physiological study. The investigators hypothesize that hyperinsulinemia is a stronger independent predictor of free testosterone (T) in older reproductive aged (vs. young) women with PCOS.
Conditions
- Polycystic Ovary Syndrome
Interventions
ACTHDrug
ACTH (Cosyntropin) 250 mcg will be given once during the study.
rhCGDrug
rhCG (Ovidrel) 250 mcg will be given once during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in calculated free testosterone concentrationsTime frame: baseline, 30 mininutes and 1 hour after adrenocorticotropic hormone (ACTH), 24 hours after recombinant human chorionic gonadotropin (rhCG).
- Mean luteinizing hormone (LH) concentrationsTime frame: overnight frequent blood sampling (every 10 mininutes for 12 hours)
- Change in ovarian 17-hydroxyprogesterone to r-hCGTime frame: baseline, and 24 hours after receiving rhCG
- Change in adrenal 17-hydroxyprogesterone to ACTHTime frame: baseline, 30 minutes, and 60 minutes after ACTH
- Mean insulin level during oral glucose tolerance testTime frame: during 2 hours of oral glucose tolerance test
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.